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I n the majority of end-stage renal disease (ESRD) patients,  phosphate binders are required to trap 
dietary phosphate and reduce its absorption,  which is 
important because hyperphosphatemia leads to various 
disorders,  including secondary hyperparathyroidism,  
soft tissue calcification,  and renal osteodystrophy [1].  
Lanthanum carbonate,  an orally administered phos-
phate binder,  is widely used for treating ESRD patients 
[2-5].  After its ingestion,  lanthanum carbonate binds 
with the phosphate in foods to form highly insoluble 
complexes.  It was reported that the insoluble com-
plexes of lanthanum phosphate are minimally absorbed 
in the gastrointestinal tract and are excreted with the 
feces [6 , 7],  but more recently,  several research groups 
have reported cases of patients with lanthanum deposi-
tion in the gastrointestinal mucosa [8-14].
Here we describe the case of a hemodialysis patient 
who was diagnosed with lanthanum phosphate deposi-
tion in the stomach.  The lesion was endoscopically 
observed as white microgranules,  and the diagnosis of 
lanthanum phosphate deposition was confirmed by 
energy dispersive x-ray spectroscopy.  Notably,  a scan-
ning electron microscopy observation (SEM) enabled 
easier identification of the deposited areas,  which were 
visible as brighter areas.  This case demonstrated the 
potential utility of SEM for the detection of lanthanum 
phosphate deposition in the gastrointestinal tract.
Case Report
A 75-year-old Japanese woman was referred to 
Okayama University Hospital for further investigation 
of bilateral hilar lymphadenopathy.  She had been 
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After having been treated with lanthanum carbonate administration for 4 years for hyperphosphatemia,  a 
75-year-old Japanese woman undergoing hemodialysis was diagnosed with lanthanum phosphate deposition in 
the stomach.  The deposition,  seen as white microgranules,  was observed using esophagogastroduodenoscopy 
with magnifying observation.  To the best of our knowledge,  these are the minutest endoscopy images of lan-
thanum phosphate deposition in the gastric mucosa.  Scanning electron microscopy (SEM) observation enabled 
easier identification of the deposited material,  which was visible as bright areas.  The present case suggests the 
usefulness of SEM observation in the detection of lanthanum phosphate deposition in the gastrointestinal tract.
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undergoing hemodialysis for 7 years for nephrosclerosis 
and had been taking oral lanthanum carbonate for 4 
years as treatment for hyperphosphatemia,  in addition 
to beraprost,  lafutidine,  mosapride,  cinacalcet,  azil-
sartan,  bisoprolol,  nifedipine,  olmesartan,  doxazosin,  
and brotizolam.  A physical examination revealed no 
abnormalities,  and no evidence of peripheral lymph-
adenopathy was detected.
Laboratory findings demonstrated elevated levels of 
soluble interleukin-2 receptor (sIL-2R) (5,489 U/mL,  
normal range: 122-496 U/mL),  angiotensin-converting 
enzyme (29.7 U/L,  normal range: 8.3-21.4 U/L),  and 
lysozyme (73.3 µg/mL, normal range: 5.0-10.2 µg/mL).  
The patient’s serum phosphate (6.0 mg/dL),  creatinine 
(9.41 mg/dL),  and blood urea nitrogen (42.9 mg/dL) 
levels were also elevated.
Subsequent 18F-fluorodeoxyglucose-positron emis-
sion tomography detected tracer uptake in the medias-
tinal,  hilar,  and porta hepatis lymphadenopathies,  and 
a transbronchial needle aspiration biopsy by bronchos-
copy demonstrated noncaseating epithelioid granulo-
ma; we therefore diagnosed the patient with sarcoid-
osis [15 , 16].
An esophagogastroduodenoscopy was performed,  
which demonstrated atrophic mucosa and two small,  
elevated lesions in the lesser curvature of the gastric 
body which were white in color (Fig. 1A,  arrows).  
Magnifying observation with narrow-band imaging 
revealed white depositions within the elevated lesions 
(Fig. 1B),  and sparse white microgranules were detected 
in the lesser curvature of the gastric body (Fig. 1A,  
arrowheads).  Magnifying observation with white light 
(Fig. 1C) and narrow-band imaging (Fig. 1D) facilitated 
a clearer view of these white microgranules.  There were 
no other mucosal alterations or evidence of sarcoid-
osis-related lesions in the stomach.
A biopsy specimen from the gastric mucosa with 
white microgranules (Fig. 1C, D) contained deposition 
of fine,  amorphous,  eosinophilic material (Fig. 2A).  
Staining for CD68 was positive in these areas,  indicat-
ing the presence of histiocytes (Fig. 2B).  For the SEM 
analysis,  a paraffin-embedded section was deparaffin-
ized with xylene (10 min,  twice) and subsequently 
washed with a serial dilution ethanol series (100% for 
5 min,  3 times; 80% for 5 min and 50% for 5 min).  
The surface of the sample was coated with osmium for 
10 sec (HPC-1S-type osmium coater; Shinku Device 
Co.,  Ibaraki,  Japan) and examined closely an S4800 
scanning electron microscope (Hitachi,  Tokyo,  Japan).
For the analysis of the elemental composition,  we 
used the S4800 scanning electron microscope to per-
form energy dispersive X-ray spectroscopy (EDAX 
Genesis APEX2 system,  Ametek,  Paoli,  PA,  USA).  
The deposited material appeared bright in the SEM 
observation (Fig. 3A).  The deposition was seen as 
aggregates of particles,  measuring 1-3 µm in diameter 
(Fig. 3B).  Elemental mapping by energy dispersive 
X-ray spectroscopy confirmed that the distribution of 
lanthanum (Fig. 3C) and phosphate (Fig. 3D) was iden-
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Fig. 2　 Pathological images of the gastric lanthanum deposition,  
as detected by hematoxylin and eosin staining.  The deposition of 
ﬁne,  amorphous,  eosinophilic material was detected (A),  and these 
areas of deposition were positive for CD68 (B).
Fig. 1　 Representative esophagogastroduodenoscopy images.  
Two small,  whitish,  elevated lesions are detected (A,  arrows).  
Magnifying observation with narrow-band imaging revealed white 
depositions (B).  White microgranules were also detected (A,  
arrowheads),  which were more clearly demonstrated by magnifying 
observation with white light (C) and narrow-band imaging (D).
tical to that of the bright areas (Fig. 3E).  Our compara-
tive analysis of the spectra between the bright areas and 
the background also demonstrated that lanthanum and 
phosphate were present in the bright areas,  whereas 
these elements were almost completely absent in the 
background mucosa (Fig. 4).  Consequently,  we diag-
nosed the gastric lesion as lanthanum phosphate depo-
sition.
The histological examination of the small elevated 
white lesions (Fig. 1A,  arrows) demonstrated foamy 
cells in the gastric mucosa (Fig. 5A , B) that were positive 
for CD68 (Fig. 5C),  which indicated that they were his-
tiocytes; thus,  a diagnosis of gastric xanthoma was 
made.  Deposition of lanthanum phosphate was not 
noted by pathologists at the initial inspection of this 
hematoxylin and eosin (H&E)-stained biopsied speci-
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Fig. 3　 SEM demonstrated that the deposited material appeared bright (A) and consisted of microparticles (B).  Elemental mapping by 
energy dispersive X-ray spectroscopy conﬁrmed that the distribution of lanthanum (C) and phosphate (D) was identical to that of the bright 
areas (E).
Fig. 4　 Spectra obtained by energy dispersive x-ray spectroscopy.  Lanthanum (arrow) and phosphate (arrowheads) were detected in the 
bright areas (A),  whereas these elements were almost or completely absent in the background mucosa (B).
men.  However,  SEM revealed the bright areas (Fig. 5D,  
arrow and arrowhead),  and energy dispersive x-ray 
spectroscopy confirmed the deposition of lanthanum 
and phosphate.  Re-evaluation of the H&E-stained 
specimen confirmed the deposition of fine,  amor-
phous,  eosinophilic material (Fig. 5E).
Discussion
Historically,  aluminum-containing compounds such 
as aluminum hydroxide were used as phosphate binders 
for dialysis patients from the 1970s.  However,  the use 
of aluminum is now contraindicated as it has been 
demonstrated that prolonged aluminum intake may 
induce encephalopathy and osteomalacia [17].  
Precipitated calcium carbonate,  polymers such as seve-
lamer hydrochloride,  and lanthanum carbonate were 
developed as phosphate binders and have been widely 
used in clinical practice [18 , 19].
In Japan,  a chewable tablet form of lanthanum car-
bonate was approved and has been marketed since 
March 2009,  and lanthanum carbonate granules were 
released to the market in May 2012.  As described 
above,  orally administered lanthanum produces insolu-
ble complexes following ionic binding to phosphate and 
prevents the absorption of dietary phosphate.  The 
majority of the insoluble complexes is thought to be 
excreted in the feces.  A phase I study was conducted to 
determine the absolute bioavailability  of orally admin-
istered lanthanum in healthy subjects,  the results of 
which demonstrated that the absolute bioavailability of 
lanthanum was extremely low,  ranging from 0.00015% 
to 0.00224% [6].
The minimal fraction of lanthanum that is absorbed 
from the intestinal tract into the systemic circulation is 
predominantly excreted in bile,  with < 2% eliminated by 
the kidneys [20].  This drug clearance by non-renal 
mechanisms allows for the safe use of lanthanum car-
bonate in patients with chronic kidney disease.
Despite the documented safety profile and tolerabil-
ity of orally administered lanthanum in humans,  sev-
eral reports have described lanthanum deposition in the 
gastrointestinal tract,  particularly in the stomach 
[8-14].  A recent retrospective study by Goto et al.  
revealed that among 14 patients who were administered 
lanthanum carbonate and underwent an endoscopic 
biopsy of the gastric mucosa,  lanthanum deposition 
was detected in 12 patients (85.7%) [12].  This result 
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Fig. 5　 Representative pathological images of the gastric xanthoma.  Foamy cells were observed in the gastric mucosa (A,B),  which 
were positive for CD68 (C).  The SEM revealed bright areas (D,  arrow and arrowhead),  and the re-evaluation of the H&E-stained specimen 
by energy dispersive x-ray spectroscopy demonstrated the deposition of ﬁne,  amorphous,  eosinophilic material (E),  which was conﬁrmed 
to be the deposition of lanthanum and phosphate.
indicates that deposition of lanthanum in the stomach 
may occur frequently in patients who are being treated 
with lanthanum carbonate.
The reported features of gastric lesions vary from 
erosions,  ulcers,  and polyps to white mucosa.  For 
example,  Yasunaga et al.  described the gastric lesion of 
a 64-year-old man with lanthanum deposition as “mul-
tiple erosions and small ulcers in the antral mucosa” 
[13]; however,  white mucosa is detectable around the 
erosions in the endoscopic images presented by those 
authors.  Similarly,  Haratake et al.  reported a gastric 
lesion as “multiple irregular erosions,” whereas white 
granules are also observable in the endoscopic image 
[11].
We therefore hypothesize that white granules are 
essential features of lanthanum phosphate deposition in 
the gastric mucosa.  The white color may be imparted by 
the aggregated particles of lanthanum phosphate itself,  
as detected by SEM in the present case.  Another possible 
explanation is that the white color is a result of histio-
cytes entrapping lanthanum phosphate.  The similarity 
of color we observed between the lanthanum deposition 
and xanthoma,  which consists of clusters of foamy his-
tiocytes,  supports the latter hypothesis.
Regardless of the mechanism that contributes to the 
white color,  to the best of our knowledge,  the endo-
scopic features demonstrated in the present case are the 
minutest lesions of lanthanum phosphate deposition in 
the gastric mucosa reported to date.  Endoscopists and 
gastroenterologists should therefore suspect this disease 
pathology when they observe white granules in the 
stomach of patients who are being treated with lantha-
num carbonate.
It is also noteworthy that our scanning electron 
microscopy observation enabled easier identification of 
deposited lanthanum in the biopsy specimen harvested 
from the xanthoma,  compared to the conventional his-
topathological evaluation of the H&E-stained section.  
As demonstrated herein,  lanthanum deposition can be 
detected histologically as fine,  amorphous,  eosino-
philic material.  Although a diagnosis of lanthanum 
deposition was made in our patient based on micro-
scopic assessment of the gastric mucosa,  which con-
tained white granules,  we suggest that SEM observa-
tion may be useful for the detection of lanthanum 
phosphate deposition in the gastrointestinal tract,  as 
these deposits can be clearly observed as bright areas.
It has been reported that the intake of several medi-
cations such as antihypertensive agents and oral iron 
supplementation results in color changes of the gastric 
and duodenal mucosa [20-22].  In this condition,  there 
is deposition of pigment within macrophages in the 
gastroduodenal mucosa.  Endoscopically,  the stomach 
and/or duodenum show dark pigmentation,  which is 
called pseudomelanosis.  Although in the present case 
we observed whitish deposition in the gastric mucosa 
(which is a different macroscopic feature than that 
occurring in pseudomelanosis),  the SEM analysis was 
useful for confirming that the deposited material was 
lanthanum phosphate rather than other chemical sub-
stances.
Conversely,  differential diagnoses of whitish lesions 
in the stomach include xanthoma,  extranodal marginal 
zone lymphoma of mucosa-associated lymphoid tissue 
(MALT lymphoma) [23],  plasmacytoma [24],  and 
crystal-storing histiocytosis [25].  These disorders are 
distinguishable from lanthanum phosphate deposition 
by a pathological analysis with appropriate immunos-
tainings.
In the present case,  a concomitant diagnosis of sar-
coidosis was made.  We believe that the co-occurrence 
of lanthanum phosphate deposition in the stomach and 
sarcoidosis detected in the lymph nodes is coincidental,  
because no sarcoidosis-related lesions were macroscop-
ically or microscopically identified in the stomach.  
Moreover,  in the previous reports of lanthanum depo-
sition in the gastrointestinal tract,  no cases had sar-
coidosis [8-14].
To date,  it is unknown whether lanthanum phos-
phate deposition in the gastrointestinal tract causes 
health problems.  Although there were no mucosal 
alterations caused by lanthanum phosphate deposition 
in the present case,  several groups have reported cases 
with erosions and/or ulcers and lanthanum deposition 
in the same gastric mucosa [11-13].  One possible 
explanation is that lanthanum deposition results in 
mucosal friability and finally leads to mucosal damage.
Yasunaga et al.  reported a case in which the patient 
presented with epigastric discomfort and gastric ero-
sions and ulcers [13].  After termination of the lantha-
num carbonate administration,  the patient’s symptoms 
were relieved and the gastric mucosal injury healed.  
This case suggests that mucosal damage is secondarily 
caused by lanthanum deposition.  Another hypothesis is 
that mucosal damage may enhance the entry of lantha-
num phosphate into the gastrointestinal mucosa [12].  
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Further studies are required to understand the pathoge-
nicity of lanthanum phosphate deposition in the gastro-
intestinal tract.
In conclusion,  we have described a case of lantha-
num phosphate deposition in the stomach,  and we 
observed the potential value of SEM for the detection of 
these deposits.  Although a histopathological examina-
tion is essential,  we suggest that the application of SEM 
may enhance the detection sensitivity of deposited 
material in patients who are receiving oral lanthanum 
phosphate.
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